Creative Biolabs rAb Blog

Menu

Skip to content
  • Therapeutic Antibody R&D
  • Recombinant Antibody R&D
  • Antibody Engineering R&D
  • News

Recombinant Antibody Products

Creative Biolabs is a pioneer of recombinant antibody (rAb) discovery and manufacture, providing the most comprehensive list of rAb products in the world. We have developed proprietary procedures for Hi-Affi™ recombinant antibody production, with optimized library construction and screening processes using hybridoma or phage display technology.

Learn More

Functional Antibody Products

At Creative Biolabs, our functional antibody products are produced and purified using specialized techniques, offering numerous features suitable for research in the activation, blocking, and neutralization of immune cell functions.

Learn More

Engineered Antibody Products

Creative Biolabs provides a diverse range of engineered antibody products, dedicated to providing clients with effective, precise, and safe antibody solutions. Our products use advanced antibody screening and engineering techniques, ensuring each one has exceptional specificity for accurately identifying targets while minimizing interference from non-specific binding.

Learn More

High Throughput Antibody Production Services

Creative Biolabs has launched high-throughput antibody production services, delivering quality antibody products to clients worldwide efficiently and rapidly. Till now, our platform has been meticulously constructed to encompass a broad range of antibody formats, from single-domain antibodies to full-length IgGs.

Learn More
30Mar/24

CD73 Inhibition: A Promising Strategy for Overcoming Immune Evasion in Colorectal Cancer

March 30, 2024Antibody Engineering R&D, Cancer ImmunotherapyColorectal Cancer, Targeting CD73biorab

Colorectal cancer (CRC) remains a leading cause of cancer-related deaths worldwide, with the likelihood of distant metastasis to the liver or lungs adding to the challenges of CRC treatment. Currently, surgical resectionRead More…

06Jan/24

A Breakthrough in Influenza Defense: Discovering Antibodies for Broad-Spectrum Protection

January 6, 2024News, Recombinant Antibody R&DInfluenza Virus, Neutralizing Antibodybiorab

The titers of antibodies that inhibit the receptor binding of hemagglutinin (HA), a key viral protein of the influenza virus, are widely recognized as directly related to protecting organisms against infection. Recently,Read More…

04Dec/23

Discovery of Highly Neutralizing Human Antibodies Targeting Pseudomonas aeruginosa for Treatment of Drug-Resistant Infections

December 4, 2023News, Therapeutic Antibody R&DNeutralizing Antibody, Pseudomonas aeruginosabiorab

Pseudomonas aeruginosa possesses multiple mechanisms of antibiotic resistance, leading to high morbidity and mortality rates. It may result in complex infections and dangerous septic cases in critically ill patients. In a recentRead More…

03Nov/23

Two New Strategies Targeting Siglec-7 Show Promise in Treating Ovarian Cancer

November 3, 2023Cancer Immunotherapy, Recombinant Antibody R&DOvarian Cancer, Siglec-7biorab

Ovarian cancer is often diagnosed in advanced stages, and its resistance to existing treatment methods poses a significant challenge. According to data from the National Institutes of Health (NIH) in the UnitedRead More…

05Oct/23

Researchers Revealed the Feasibility and Clinical Prospects of Targeting SLC7A11 for the Treatment of Osteosarcoma

October 5, 2023Cancer ImmunotherapyOsteosarcoma, SLC7A11biorab

Osteosarcoma (OS) is the most common malignant bone tumor, primarily affecting adolescents. In the 1970s, the clinical use of chemotherapy in conjunction with surgical resection significantly improved the five-year survival rate ofRead More…

02Sep/23

Controlling Widespread Neutralizing Antibodies Produced in Post-Treatment Controllers Promotes Long-Term Remission of HIV-1 Infection

September 2, 2023News, Therapeutic Antibody R&DHIV-1 Infection, Neutralizing Antibodiesbiorab

Some HIV-1 carriers who received early antiretroviral therapy (ART) for several years can maintain long-term control over the virus after treatment interruption. However, the mechanism behind this post-treatment control is not fullyRead More…

01Aug/23

Scientists Identify Special Genes Capable of Producing a Large Number of Key Antibodies

August 1, 2023Cancer Immunotherapy, Therapeutic Antibody R&DAntibody Productionbiorab

Cellular secretions play various crucial roles within the body. However, methods to connect this functional information with surface markers and the transcriptome have been lacking. In a recent research paper published inRead More…

14Jul/23

Targeting Integrins for the Treatment of Drug-Resistant Acute Myeloid Leukemia

July 14, 2023Cancer ImmunotherapyAcute Myeloid Leukemia, Integrinbiorab

Acute myeloid leukemia (AML) remains highly resistant to treatment with a high relapse rate, necessitating the development of new therapeutic strategies. Integrin-targeted therapy, which has been extensively studied in solid tumors andRead More…

29Jun/23

The Roles of Loss of CXCR2 Expression/Activity in Melanoma Tumorigenesis

June 29, 2023Cancer ImmunotherapyCXCR2, Melanoma Tumorigenesisbiorab

Chemokines and their receptors have been shown to play crucial roles in regulating tumor growth, progression, metastasis, and response to immunotherapy. Initially known for their role as chemoattractants in guiding leukocyte migration,Read More…

12May/23
Targeting PD-L2–RGMb overcomes microbiome-related immunotherapy resistance

Targeting PD-L2-RGMb Promises to Enhance the Efficacy of Cancer Immunotherapy

May 12, 2023News, Therapeutic Antibody R&DCancer Immunotherapy, Targeting PD-L2-RGMbbiorab

Immunotherapy has revolutionized the treatment of many cancer types. However, for reasons that remain poorly understood, not all patients respond equally from these potent therapies. In a recent study, researchers from HarvardRead More…

Posts navigation

  • 1
  • 2
  • 3
  • 4
  • Next »

Categories

  • Antibody Engineering R&D
  • Cancer Immunotherapy
  • News
  • Recombinant Antibody R&D
  • Therapeutic Antibody R&D

Recent Posts

  • CD73 Inhibition: A Promising Strategy for Overcoming Immune Evasion in Colorectal Cancer
  • A Breakthrough in Influenza Defense: Discovering Antibodies for Broad-Spectrum Protection
  • Discovery of Highly Neutralizing Human Antibodies Targeting Pseudomonas aeruginosa for Treatment of Drug-Resistant Infections
  • Two New Strategies Targeting Siglec-7 Show Promise in Treating Ovarian Cancer
  • Researchers Revealed the Feasibility and Clinical Prospects of Targeting SLC7A11 for the Treatment of Osteosarcoma

Archives

Contact Us

USA – UK

Copyright © Creative Biolabs rAb Blog
Powered by WordPress , Theme i-max by TemplatesNext.
MENU
  • Therapeutic Antibody R&D
  • Recombinant Antibody R&D
  • Antibody Engineering R&D
  • News